Open access peer-reviewed chapter

Defining Microglial Phenotypes in Alzheimer’s Disease

Written By

Douglas Walker and Lih-Fen Lue

Submitted: 02 November 2017 Reviewed: 15 February 2018 Published: 18 July 2018

DOI: 10.5772/intechopen.75511

From the Edited Volume

Alzheimer's Disease - The 21st Century Challenge

Edited by Jolanta Dorszewska and Wojciech Kozubski

Chapter metrics overview

1,128 Chapter Downloads

View Full Metrics


The concept of activated microglia being associated with neurodegenerative pathological structures in aging and Alzheimer’s disease (AD) has been well established, but questions remain about how well are we defining “what are microglia actually doing” when we look at diseased or aged brains? Most studies of microglia in human AD brains have employed a limited set of antigenic markers, particularly the major histocompatibility complex protein HLA-DR and ionized calcium-binding adaptor molecule IBA-1, along with cellular morphological criteria, but in recent years, it has been appreciated that microglial responses are very heterogeneous depending on their surrounding environment—every microglia might be different. Initial observations on human brain microglia associated with plaques and tangles suggested that microglial inhibition with broad spectrum anti-inflammatory drugs should slow down AD pathology, but clinical trials did not show this approach to be effective. In this article, we will consider the needs, challenges and benefits for refining how microglia are defined as they associate with pathological proteins. This may aid in defining which ones are accelerating neurotoxicity and which ones are performing reparative/phagocytic functions. More complete definition of microglial phenotypes offers the potential of developing targeted anti-inflammatory approaches for this disease.


  • neuroinflammation
  • pathology
  • immunohistochemistry
  • antibodies
  • activation
  • microglia

1. Introduction

Progress in developing new treatment approaches for Alzheimer’s disease (AD) has been slow. The goals of identifying key pathological events early in the disease and preventing them from progressing further has been investigated for many approaches; including preventing amyloid formation and/or aggregation [1, 2], preventing tau phosphorylation and aggregation [3], reducing mitochondrial dysfunction and production of reactive oxygen species with various anti-oxidants [4, 5], enhancing autophagy [6], reducing the consequences of abnormal lipid metabolism [7], and targeting inflammation and microglia [8] amongst others with limited effectiveness. Since the identification of increased inflammation in AD brains, first characterized more than 30 years by increased expression by microglia of HLA-DR [9], and subsequently for other macrophage proteins, including beta II integrins and immunoglobulin Fc receptors CD16, CD32 and CD64 [10, 11], ferritin [12, 13], CD68 [14, 15] amongst others, led to the development of the inflammation hypothesis for AD that suggested that inflammatory products were driving the loss of synapses and neurons in this disease [16]. If this were true, reducing inflammation should have shown great potential for treating AD, however; this approach has not been successful to date [17, 18].

The initial studies identified several features about the microglia associated with AD plaque and tangle pathology. There was increased expression of the MHC class II marker HLA-DR, and morphologically the microglia were different with thicker cell processes and enlarged cell bodies [19]. From these initial observations, it was concluded that the microglia were in a pro-inflammatory state and thus must be producing neurotoxic cytokines that would be accelerating the progression of disease. This hypothesis is illustrated in Figure 1, where in this illustration aggregated amyloid beta (Aβ) peptide, produced as an initial feature of AD, activates the microglia, which can produce cytokines such as tumor necrosis factor (TNF)-α or interleukin (IL)-1β that accelerate neuronal dysfunction. This scheme was supported by experimental studies showing that aggregated/fibrillar Aβ had strong proinflammatory-inducing properties on microglia, including activation of the NADPH oxidase complex of myelocytic cells that leads to a burst of production of highly toxic reactive oxygen species [20, 21], as well as induction of many proinflammatory genes [22]. Another feature of this figure, which could be as important, is the other (non-proinflammatory) microglia that will be present in the AD pathological environment. There has been insufficient attention to describing these microglia, but they will play an essential role in phagocytosis of Aβ as well as performing other homeostatic functions. It has been hypothesized that one could distinguish between these microglia based mainly on cellular morphology; however there are limited data to support this. The presence of activated microglia in AD tissues provided the rationale for testing of “non-specific” non-steroidal anti-inflammatory drugs (NSAIDS) in AD patients. There had been supporting, though not unanimous, data that subjects with a history of long term anti-inflammatory drug usage also seemed to be protected from dementia [23, 24, 25]. Controlled drug trials of NSAIDs or related agents in AD patients have never shown significant effectiveness in slowing disease progression, and even these widely-used agents appear to have significant side effects in elderly subject. It has been argued that these trials failed because the disease was too far progressed to respond to therapy, but we will posit in this article that maybe our understanding of the unique features of inflammation in AD are still not complete enough for selecting appropriate drug treatments. This comes back to the central question of “what are the activated microglia actually doing” in the AD brain [17, 18]. Such studies need adequate numbers of quality tissue samples from control and AD cases. The presence of AD plaque and tangle pathology is also a common feature in aged brains without clinical dementia. These cases, called high pathology controls or high plaque non-demented, are particularly valuable for neuroinflammation studies as they provide material for studying what might be pre-AD stages of microglial activation. Being able to describe progression of inflammatory changes leading AD could be critical for identifying therapeutic targets.

Figure 1.

Microglia are performing multiple functions in Alzheimer’s disease brains. How should microglia be classified in human brains. Scheme to illustrate the potential change in activation of microglia with development of disease. The morphologies of resting or surveilling microglia is established, but it is apparent that activated-cytotoxic-microglia in brain tissue may be indistinguishable from the activated-reparative or -phagocytic microglia. The observation of ameboid microglia in AD tissue without other pathology (infarcts/hemorrhage) involving lymphocyte infiltration is rare.


2. Dichotomy of microglial function: do we know which microglia are producing damaging inflammation and which are performing phagocytosis of damaging abnormal proteins

Since the initial discoveries of activated microglia in AD and aging brains, the concepts and knowledge of what microglia are doing or could potentially be doing has progressed. The central role of microglia in brain, or macrophages in general, is to phagocytose and digest cellular waste products, which should include the extra-cellular Aβ that is deposited in AD and aging brains. An important question that is still unanswered today is “why are microglia not doing a better job of removing Aβ plaques?” Some concepts of microglial function in relation to AD came from transgenic mouse models using animals engineered to develop Aβ plaques in a manner similar to humans. These studies produced some conflicting results, but in general it was shown that microglia could be manipulated to achieve greater removal of plaque material, but in these mice, as in humans, microglial removal of plaque material is not efficient without some stimuli [26]. Again, we can ask does this apply to all microglia? Certain cytokine treatments affect microglia leading to reduced phagocytosis such that plaque material accumulates to a greater extent [27, 28, 29]. These studies illustrated how microglia can be activated to be more or less efficient at Aβ removal [30, 31]. This was particularly shown in Aβ-peptide immunized mice, which had produced a specific antibody response to plaque material. The coating of plaques with anti-Aβ immunoglobulin appeared to promote phagocytosis through engagement of the microglial IgG Fc receptors. Overall, these studies showed that microglia of a particular phenotype have the potential to remove Aβ; similar observations have come from human pathological studies in certain subjects who had received the Aβ vaccine [14].


3. Schemes for defining microglial function: limitations of M1 and M2 activation state definitions

Phenotyping of macrophages and microglia progressed with the pioneering work of Gordon and colleagues who sought to develop schemes for classification of macrophages, first in mice and then in humans, by assigning activation states to the expression of different antigenic markers based on responses to defined activation stimuli [32, 33]. Much of this work employed gene expression profiling mRNA analysis since these techniques have fewer of the limitations associated with antibodies that will be discussed. These phenotyping schemes were also applied to microglia, both rodent and human. The scheme defined classical activation or M1 activation, as being the state of macrophages/microglia that have been stimulated with strong inflammatory agents such as lipopolysaccharide (LPS) and interferon gamma (IFN-γ). Such activated cells will be expressing increased levels of cytokines and enzymes such as TNF-α, IL-1β, IL6, matrix metalloproteinase (MMP)-3 and MMP-9. The corollary to this is alternative activation or M2, which defines the markers and products of cells responding to anti-inflammatory cytokines such as IL-4 or IL-13. These cells have a reparative/neurotrophic phenotype and can produce growth factors. Such reparative M2 microglia also show increased phagocytosis. The M2 scheme was further subdivided into M2a (responses to IL4 or IL13), M2b (responses to immune complexes in combination with IL-1β or LPS) and M2c (responses to anti-inflammatory IL-10, TGFβ or glucocorticoids). It was shown that increased expression of the scavenger receptor CD163, a marker for M2c was upregulated in microglia in AD and Parkinson disease dementia cases. This is the first study showing a type of alternative activation in AD tissues by immunohistochemistry [34].

Many studies have tried to apply these schemes to tissue microglia but their validity has been contested [35]. The schemes are dependent on using defined stimuli, while in the degenerating AD brain, there will be many different stimuli (Aβ and tau in different conformations, reactive oxygen, cytokines, bioactive lipids, ATP/ADP, DNA, etc.) that will account for the heterogeneity of microglia responses in tissue. In recent years, there has been criticism that the M1 and M2 scheme is not applicable for tissue microglia as such defined microglia do not seem to exist in brain [35]. This may be correct as the microenvironment around every plaque and every neuron will be different, but to attempt to profile microglia does require some form of scheme, even an imperfect one, to relate to function. It will also be proposed that the limitations of the M1 and M2 classification schemes could be due to technical reasons as much as biological reasons.


4. Practical issues involved in microglial phenotyping in human autopsy brains

Success in classifying microglia in postmortem human autopsy tissue sections is primarily dependent on the antibodies being used for this purpose, but also the manner in which the brain tissue being studied was preserved. Many published studies of microglial markers for immunohistochemistry have been restricted to antibodies that produce strong immunoreactivity on extensively fixed tissue sections. This is particularly true for HLA-DR, which is the most widely used for human microglial studies, as available antibodies can produce vivid results on a wide range of preserved brain tissue. The following references are the first for HLA-DR and the most recent, spanning 30 years of studies [36, 37]. The function of HLA-DR in AD microglia is still unclear. This protein functions to present processed antigens to T lymphocytes that are not present in the AD microenvironment. The signaling that leads to upregulation of HLA-DR in AD microglia has not been defined. In recent years, the marker IBA-1, which recognizes an actin-binding protein involved in cytoskeletal reorganization and cell motility, has also been extensively used to identify microglia because of the availability of robust staining antibodies [38]. IBA-1 antibodies seem to recognize all microglia with limited upregulation in activated microglia, though this interpretation is also dependent on observations related to microglial morphology. The use of antibodies that produce strong results in tissue sections may have biased our understanding of microglial function in disease as many other antigenic markers are present, but suitable antibodies to reveal them in tissue are not available. Most useful markers of function are cell-surface glycosylated proteins whose antigenicity become significantly affected by fixation conditions and also by the degree of glycosylation. The most widely available tissues for many researchers are tissue blocks that have been formalin-fixed for extended periods and then embedded in paraffin (FFPE); this process includes treatments with xylene. These preservation methods strongly affect the ability of antibodies to recognize many antigens, but in particular cell-surface glycoproteins. The numbers of antibodies that are effective at antigen recognition on FFPE tissue are a small percentage of available antibodies. In addition, the use of FFPE tissue usually requires the application of antigen retrieval techniques for most antibodies to work; there are a range of these methods but their successful application is dependent on operator skill and can lack reproducibility. As mentioned, the applicability of M1 and M2-like schemes to classify microglia in human brain samples has been criticized as many of the classification antigens have not been proven in tissue microglia [35], however such schemes may have been prematurely discarded due to the lack of panels of antibodies functional on available brain tissue samples.

4.1. Previous studies of microglial functional proteins in AD

Since the initial studies of increased HLA-DR expression by microglia in AD brains, in areas associated with pathology [9, 19, 36, 39, 40, 41, 42], expression of a range of macrophage markers have been applied to AD brain tissues. These include beta II integrins (CD11a, b, and c and CD18—complement and phagocytic receptors), immunoglobulin Fc receptors (CD16, CD32, CD64) [11], lipopolysaccharide receptor CD14 [43], macrophage colony stimulating factor receptor-1 (CSF-1R; CD115) [44], type B scavenger receptor CD36 [45, 46], ferritin [47], signal regulatory protein beta-1 (SIRPβ-1) [48] and progranulin [49]. The markers CD43 and TMEM106B were shown to be downregulated in AD microglia compared to controls [50, 51]. This represents an incomplete list due to space limitations but many of these markers are related to phagocytic function rather than cytotoxicity. Ferritin has unique properties in relation to microglial activation as it is a ubiquitous iron transport protein but in tissue seems to selectively identify a population of activated microglia [12, 13]. To directly demonstrate potential cytotoxicity, the demonstration of increased levels of cytokines in microglia is needed. Over the last 30 years, there have been few studies using immunohistochemistry to profile cytokines in tissue sections. A series of studies by Griffin and colleagues showed IL-1α-expressing microglia were associated with different types of plaques and tangles. Diffuse neuritic and non-neuritic plaques had the most IL-1α positive microglia, while dense core neuritic and non-neuritic plaques had significantly few IL-1α positive microglia. These results suggest that this population of microglia were involved at early stages of plaque formation [52]. Use of this marker demonstrated that IL-1α positive microglia were involved in the generation of neurofibrillary tangles in the parahippocampal gyrus [53]. In another study, it was shown that IL-1β and TNF-α could be localized to microglia in human AD tissue [42]. The limited numbers of studies do highlight the technical difficulties of detecting secreted proteins such as cytokines. Griffin and colleagues employed FFPE tissue for immunohistochemistry. We have attempted a number of times using our short-fixed microtome cut sections to localize cytokines to tissue and have never been successful. As these molecules are secreted rather than membrane localized, it is possible the hard fixation involved in FFPE is needed to anchor them, and then antigen retrieval to allow antibody access. With short fixed brain tissues materials, these soluble proteins might not be adequately fixed in situ for localization.

4.2. Selecting antibodies for microglial phenotyping

The whole field of human brain immunohistochemistry has several limitations when it comes to selection of suitable antibodies needed to reveal location of proteins of interest. Firstly, the antibody, usually a monoclonal antibody of mouse or rabbit origin, thus specific to an epitope representing a small portion of the target protein, has to be able to show specificity—namely it is actually recognizing the target protein in situ and not cross reacting with other proteins. Secondly, the antibody, if it can be validated to recognize the target protein in tissue, its specificity and sensitivity can be affected by the fixation conditions. In our experience, the study of microglial antigens with a wider range of antibodies has been less problematic using brain tissue fixed for a short period (48 h) in paraformaldehyde (not formalin) and then cryoprotected and sectioned using a freezing microtome. This process avoids the harsh treatments involved in paraffin embedding of tissue. Over the years, we have successfully identified microglial proteins CD87 [54], RAGE, CD33 [55], TREM-2 [56], TLR-2, -3, -4 along with HLA-DR, IBA-1, CD68 in AD tissues.

Our experience with antibodies when using these tissues identified some features that help increase the chances of successful immunolocalization. One company—R & D Systems—Biotechne, Minneapolis, MN—have produced many of their antibodies using a relatively unique strategy for the industry. Many of their antibodies were prepared from proteins of interest expressed in eukaryotic cells. These proteins will be glycosylated in a similar manner to what might be expected in human tissues. In addition, the immunizing proteins usually cover the majority of the native protein, and thus preserve some of the secondary protein structure that affects antigenicity, along with containing multiple antigenic epitopes. These proteins produce antibodies with immunogenicity superior to the strategy of many companies that use short synthetic peptide sequences of 10–20 amino acids as immunogens, and then conjugated to a carrier prior to animal immunization. Our experience with R & D Systems affinity purified polyclonal antibodies has generally been favorable for use on lightly-fixed tissues. These antibodies will contain a range of epitopes that can increase the likelihood of identifying epitopes on proteins not severely affected by fixation. The use of large protein antigens to prepare polyclonal does have some drawbacks as there is the potential for cross reactivity with other related proteins. Quality control is dependent on being able to carry out protein absorption of antibody to show removal of tissue reactivity, along with western blot detection of specific protein bands.

Figure 2 (panels A and B) illustrates our experience using an R & D Systems antibody to Toll-like receptor (TLR)-3 (AF1487) to identify microglia in AD brains, and an R & D Systems polyclonal antibody to CD206 (AF2535), which failed to identify microglia (panels D and E). The TLR-3 polyclonal antibody could identify structures in human brain microglia (Figure 2, panels A and B). One comment is that if western blots are carried out using complex material such as brain material, the presence of other protein bands, besides the full length protein should be anticipated (Figure 2, panel C). Most functional proteins are either cleaved during their normal function, for example loss of leader sequences, cleaved to produce secreted forms, or broken down as part of cellular metabolism. Interestingly, a monoclonal antibody to TLR-3 produced with the same immunizing protein could not stain microglia in tissue, but this antibody will be specific for only a single epitope present in the immunizing protein. We have had similar experience with an R &D systems antibody to CD206 (Figure 2, panels D and E), also known as macrophage mannose receptor, produced against a eukaryotic cell expressed protein. This protein has been defined as a prototypical marker for M2a alternative activation as its expression is induced in the presence of IL-4. We used this antibody to determine if there was evidence for alternative activation microglia in human brains. Using this antibody, which on western blots could detect specific bands on brain samples, did not identify microglia in any of the control or AD tissue sections we stained. Noticeable however was the strong CD206 staining of round cells (perivascular macrophages) located within or around the vessels present in the brain sections. This is similar to a published finding [34]. This seems to indicate alternative activated macrophages are common in vessels, while alternative activated microglia are not present in neuropil. In human brains, identifying expression of inflammatory associated molecules at the RNA or protein level using brain homogenates need to be interpreted with caution as significant numbers of blood cells can be trapped within the tissue [57]. Confirmation of findings by immunohistochemistry is needed when making observations relevant to microglia. The absence of alternative activated markers in AD brain samples was confirmed for the CD200 receptor (CD200R). This is a myeloid specific receptor that is activated by the ligand CD200 to induce anti-inflammatory signaling. We showed that it was induced by IL-4 and IL-13 and fit the classical definition of an M2a marker, similar to CD206. Using several antibodies, including R&D Systems polyclonal antibody (AF3414) and a custom peptide antibody, we could not localize CD200R immunoreactivity to brain microglia even though protein and mRNA expression of CD200R are detectable in human brains [58].

Figure 2.

Approaches to microglial phenotyping in Alzheimer’s disease brains. (A) and (B) Immunohistochemistry for a new marker for microglia (toll-like receptor-3: TLR-3 in human brains. Double immunostaining for TLR-3 (purple) colocalizing with IBA-1 microglia in (A) non-demented control middle temporal gyrus and (B) Alzheimer’s disease case. See text for further explanation. These findings were obtained using R&D Systems antibody (AF1868). (C) Western blot of human brain samples for TLR-3. This panel illustrates that protein bands other than full length peptides can be present in biological samples. (D) and (E) Absence of alternatively activated microglia expressing CD206 in ND (D) or AD (E) temporal cortex brain sections but positive expression in perivascular/vascular macrophages. (F) and (G) The proinflammatory marker CD14 does show increased expression by microglia in AD cases (purple) colocalizing with IBA-1 immunoreactivity brain Strong positive staining is present in perivascular/vascular macrophages (purple) is also a feature.

One marker that seems to have been overlooked in microglial profiling in tissue is CD14, the LPS co- receptor. This receptor is a classical M1-like activation marker with upregulation associated with proinflammatory activation. There has only been a single study describing microglial immunohistochemistry in human AD brains for CD14 [43]. Using short fixation tissue, we reexamined expression of this marker (Figure 2, panels F and G). It is strongly expressed by most vascular macrophages of all cases (Figure 2, panel F—ND case), but increased expression was readily detectable in subsets of IBA-1 microglia in AD cases (Figure 2, panel G—purple). As CD14 can bind Aβ with proinflammatory activation through interaction with TLR-2 or TLR-4, increased CD14 expression could be a more used marker for defining cytotoxic microglia.

4.3. Profiling TREM-2 microglia in human brains

This discussion is of particular relevance for considering microglial phenotyping of TREM-2 positive microglia. Considerable interest in the role of TREM-2 in AD has spurred new interest in neuroinflammation and AD. A single nucleotide polymorphism (SNP) in the TREM-2 gene (rs75932628) that results in a mutation in the TREM-2 protein (R47H) can increase the risk of developing AD by 2- to 11-fold depending on the population studied [59, 60]. Mutations in TREM-2 or its adaptor protein DAP12 were first identified in Nasu-Hakola disease, which leads to early onset dementia amongst other symptoms [61]. The mutation appears to lead to loss of function of the TREM-2 protein, whose normal function is to promote phagocytosis of apoptotic neurons through binding to heat shock protein 70 (hsp70) or different conformations of lipids. There have been few studies of immunohistochemistry of TREM-2 in human AD brains, which appears mainly due to lack of robust antibodies for pathological work. We published one of the first studies that showed plaque- and tangle-associated microglia were positive for TREM-2 [56]. In this study, we had to screen a number of antibodies for specificity and sensitivity in human brain tissue. The best results were obtained with an R&D Systems polyclonal antibody to TREM-2 (AF1828) prepared using a eukaryotic cell expressed protein corresponding to 75% of the protein and to the complete extracellular domain. A recent study of TREM-2 expression in AD frontal cortex using an antibody prepared using a peptide corresponding to N-terminal amino acids 29–59 of human TREM2 (ab175262, Abcam, Cambridge, MA) showed specificity by western blots, but these authors presented no data on TREM2 immunohistochemistry [62]. TREM-2 expression is restricted to dendritic/myeloid cells and is high in brain microglia. Specificity of commercial antibodies has been an issue, but also the sensitivity of detection. Two studies have concluded that TREM-2 was not expressed by microglia in brain, but both studies employed FFPE tissue samples with antigen retrieval [63, 64]. One study showed that the R&D antibody was specific for TREM-2, similar to our published work, but they could not demonstrate microglial TREM-2 immunoreactivity [63]. Similar to our previous studies, we employed lightly fixed brain tissues that were not paraffin-embedded [56]. With these sections, we could demonstrate specific TREM2 localization to microglia [56]. Our finding is reasonable as TREM-2 has been localized to plaque-associated microglia in AD model transgenic mice [65].


5. Does expression of antigen correlate with identifiable function

How does antigen expression relate to demonstrated microglial function? With the exception of HLA-DR and IBA-1, most studies of microglia in human brains have not been adequately replicated. Immunohistochemistry is not a quantitative technique due to the amplification technologies used along with the non-availability of standards for comparison, but the studies by Boche and colleagues using semi-quantitative measures deserve mention [10, 14, 66, 67]. Using a large series of brain samples and the expression of different markers, including CD64, MSR-A, CD68, HLA-DR and IBA-1, it was shown that microglia could be subtyped depending on their profile. These studies set the standards for microglial profiling in human brains. These studies employed two measures for analysis; the area of immunoreactivity and the numbers of positive cells. These studies attempted to assign phagocytic function or activation function to the microglia in relation to the type of pathology. One interesting observation was the lack of significant correlation between expression levels of these different antigens by microglia. These markers are related to different functions, with CD64, MSR-1, and C68 being related to phagocytosis, HLA-DR with antigen presentation and IBA-1 with microglial motility. Studies of TREM-2 and CD33 in AD brains demonstrated upregulated expression in AD brains, but both receptors induce inhibitory signaling when activated [55, 56]. There is evidence that upregulation of such activated microglial proteins encountered in disease tissue could be to have an inhibitory effect on inflammation, not amplifying inflammatory responses.

5.1. Where are the non-activated microglia in AD or aging brains?

In recent years, gene discovery methodology (RNA sequencing, microarrays, single cell sorting) has been applied to studies of microglia. One particularly interesting marker identified is the purinergic ADP/ATP receptor P2RY12. This was shown to be highly expressed by microglia (human and rodent) compared to macrophages. In addition, it appears to be a marker of non-activated microglia as expression becomes rapidly downregulated upon inflammatory activation with LPS [68]. P2RY12 has been defined as a M2 marker as it is unregulated in vitro in human microglia by treatment with IL-4 [69]. A common concept over the years about neuroinflammation and AD is that widespread proinflammatory activation is a significant and extensive feature. The expression that the brain is on fire has been used more than once in review articles of AD inflammation. If inflammation is widespread in pathological affected tissues, one would expect that P2RY12 expression would be very low or absent in AD brains. Our preliminary findings show that this is not the situation; there were many P2RY12 microglia in regions with severe AD pathology. Although western blot and mRNA studies showed no difference in expression of this gene between AD and control samples, however by immunohistochemistry, there was a very specific distribution of P2RY12 positive and negative microglia in brains in relation to pathological structures.


6. Future directions

The potential benefits for complete definition of microglial phenotypes by immunohistochemistry in human brains could be significant. The development of effective inflammation-focused therapies for AD requires the identification of therapeutic targets that are relevant to the human disease, not to models of disease in a transgenic animal or cell culture. AD is a uniquely human disease of the elderly, with pathology having developed for years before dementia becomes observable. In transgenic models, disease pathology can develop over weeks. There have been many agents that can reverse plaque development and inflammation in AD mice models that have failed to be effective in humans. There are many challenges involved in human focused studies, but the benefits of having human disease targets validated in human tissue could involve significant saving in time and resources from pursuing the wrong approaches. Immunohistochemistry is not considered a state of art technique in the twenty-first century as the technologies have not much changed in 30 years, but ultimately it is required to show that gene discovery findings are valid. The need for large numbers of high quality human tissue samples has been one limitation, but this can be addressed by collaborative studies. Brain tissue that has been consistently prepared with appropriate clinical and pathological records allow studies involving progressive changes in pathology from negligible to severe rather than the less useful classification of control or AD. There is also a need for improved expectations on the performance of antibodies. The performance and reproducibility of antibodies in all biological experiments has been a growing concern [70], but ultimately it is the responsibility of the experimenter/pathologist to determine the suitability of antibodies used to make a unique observation. The field of neuroinflammation in AD has been reinvigorated with discoveries about TREM-2 having a direct link to AD risk. To be able to reliably identify TREM-2 positive microglia in brain is needed to fully understand its role in sporadic AD, and validate the large numbers of model studies that have proposed therapeutic strategies for AD focused on TREM-2.


7. Conclusions

Microglia represent approximately 10% of the total cell population in human brain, but it is now appreciated how complex their responses are to pathological stimuli and for maintaining healthy neurons. Treating pathological inflammation in AD with broad spectrum agents (e.g., cyclooxygenase inhibitors) may do more harm than good. If the microglial responses to pathology are highly dependent on the microenvironment; for example one microglia may be producing excess TNF-α while an adjacent one is attempting to remove the pathological stimuli, then treatments need to be targeted appropriately. This will only be possible if the microglia actively involved in AD can be adequately profiled.



The work on TLR-3 was supported by a grant to author from National Institutes of Health, National Institutes on Aging (1R21AG044068). The human brain sections were provided to author from the Banner Sun Health Research Institute Brain and Body Donation Program. The operation of the Banner Sun Health Research Institute Brain and Body Donation Program has been supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson’s Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer’s Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer’s Research Center), the Arizona Biomedical Research Commission (Contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson’s Disease Consortium) and the Michael J. Fox Foundation for Parkinson’s Research (The Prescott Family Initiative).


  1. 1. Han X, He G. Toward a rational design to regulate beta-amyloid fibrillation for Alzheimer’s disease treatment. ACS Chemical Neuroscience. 2018;9:198-210. DOI: 1021/acsche-mneuro.7b00477
  2. 2. Prati F, Bottegoni G, Bolognesi ML, Cavalli A. BACE-1 inhibitors: From recent single-target molecules to multitarget compounds for Alzheimer’s disease. Journal of Medicinal Chemistry. 2017;10. DOI: 1021/acs.jmedchem.7b00393
  3. 3. Das S, Basu S. Multi-targeting strategies for Alzheimer’s disease therapeutics: Pros and cons. Current Topics in Medicinal Chemistry. 2017;17:3017-3061. DOI: 10.2174/1568026617666170707130652
  4. 4. Nesi G, Sestito S, Digiacomo M, Rapposelli S. Oxidative stress, mitochondrial abnormalities and proteins deposition: Multitarget approaches in Alzheimer’s disease. Current Topics in Medicinal Chemistry. 2017;17:3062-3079. DOI: 10.2174/1568026617666170607114232
  5. 5. Cascella M, Bimonte S, Muzio MR, Schiavone V, Cuomo A. The efficacy of epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: An overview of pre-clinical studies and translational perspectives in clinical practice. Infectious Agents and Cancer. 2017;12:36. DOI: 10.2174/1568026617666170607114232
  6. 6. Wu M-Y, Song J-X, Wang S-F, Cai C-Z, Li M, Lu J-H. Selective autophagy: The new player in the fight against neurodegenerative diseases? Brain Research Bulletin. 2017;137:79-90. DOI: 0.1016/j.brainresbull.2017.11.009
  7. 7. Rojas-Gutierrez E, Munoz-Arenas G, Trevino S, Espinosa B, Chavez R, Rojas K, et al. Alzheimer’s disease and metabolic syndrome: A link from oxidative stress and inflammation to neurodegeneration. Synapse. 2017. DOI: 10.1002/syn.21990
  8. 8. Ardura-Fabregat A, Boddeke EWGM, Boza-Serrano A, Brioschi S, Castro-Gomez S, Ceyzeriat K, et al. Targeting neuroinflammation to treat Alzheimer’s disease. CNS Drugs. 2017;31:1057-1082. DOI: 10.1007/s40263-017-0483-3
  9. 9. McGeer PL, Kawamata T, Walker DG, Akiyama H, Tooyama I, McGeer EG. Microglia in degenerative neurological disease. Glia. 1993;7:84-92. DOI: 10.1002/glia.440070114
  10. 10. Minett T, Classey J, Matthews FE, Fahrenhold M, Taga M, Brayne C, et al. Microglial immunophenotype in dementia with Alzheimer’s pathology. Journal of Neuroinflammation. 2016;13:135. DOI: 10.1186/s12974-016-0601-z
  11. 11. Akiyama H, McGeer PL. Brain microglia constitutively express beta-2 integrins. Journal of Neuroimmunology. 1990;30:81-93
  12. 12. Roe MT, Dawson DV, Hulette CM, Einstein G, Crain BJ. Microglia are not exclusively associated with plaque-rich regions of the dentate gyrus in Alzheimer’s disease. Journal of Neuropathology and Experimental Neurology. 1996;55:366-371
  13. 13. Kaneko Y, Kitamoto T, Tateishi J, Yamaguchi K. Ferritin immunohistochemistry as a marker for microglia. Acta Neuropathologica. 1989;79:129-136
  14. 14. Zotova E, Bharambe V, Cheaveau M, Morgan W, Holmes C, Harris S, et al. Inflammatory components in human Alzheimer’s disease and after active amyloid-beta42 immunization. Brain. 2013;136:2677-2696. DOI: 10.1093/brain/awt210
  15. 15. Wojtera M, Sobow T, Kloszewska I, Liberski PP, Brown DR, Sikorska B. Expression of immunohistochemical markers on microglia in Creutzfeldt-Jakob disease and Alzheimer’s disease: Morphometric study and review of the literature. Folia Neuropathologica. 2012;50:74-84
  16. 16. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer’s disease. Neurobiology of Aging. 2000;21:383-421
  17. 17. Lyketsos CG, Breitner JCS, Green RC, Martin BK, Meinert C, Piantadosi S, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800-1808. DOI: 10.1212/01.wnl.0000260269.93245.d2
  18. 18. Meinert CL, Breitner JCS. Chronic disease long-term drug prevention trials: Lessons from the Alzheimer’s disease anti-inflammatory prevention trial (ADAPT). Alzheimer's & Dementia. 2008;4(Suppl. 1):S7-S14. DOI: 10.1016/j.jalz.2007.10.007
  19. 19. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. Journal of Neuroimmunology. 1989;24:173-182
  20. 20. Klegeris A, Walker DG, McGeer PL. Activation of macrophages by Alzheimer beta amyloid peptide. Biochemical and Biophysical Research Communications. 1994;199:984-991. DOI: 10.1006/bbrc.1994.1326
  21. 21. Bianca VD, Dusi S, Bianchini E, Dal Pra I, Rossi F. Beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer’s disease. The Journal of Biological Chemistry. 1999;274(22):15493-15499
  22. 22. Walker DG, Link J, Lue L-F, Dalsing-Hernandez JE, Boyes BE. Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. Journal of Leukocyte Biology. 2006;79:596-610. DOI: 10.1189/jlb.0705377
  23. 23. Breitner JCS, Haneuse SJPA, Walker R, Dublin S, Crane PK, Gray SL, et al. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology. 2009;72:1899-1905. DOI: 10.1212/WNL.0b013e3181a18691
  24. 24. Wang J, Tan L, Wang H-F, Tan C-C, Meng X-F, Wang C, et al. Anti-inflammatory drugs and risk of Alzheimer’s disease: An updated systematic review and meta-analysis. Journal of Alzheimer's Disease. 2015;44:385-396. DOI: 10.3233/JAD-141506
  25. 25. in t’ Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. The New England Journal of Medicine. 2001;345(21):1515. DOI: 10.1056/NEJMoa010178
  26. 26. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature. 2000;408:979-982. DOI: 10.1038/35050110
  27. 27. Chakrabarty P, Tianbai L, Herring A, Ceballos-Diaz C, Das P, Golde TE. Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Molecular Neurodegeneration. 2012;7:36. DOI: 10.1186/1750-1326-7-36
  28. 28. Chakrabarty P, Ceballos-Diaz C, Beccard A, Janus C, Dickson D, Golde TE, et al. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. Journal of Immunology. 2010;184:5333-5343. DOI: 10.4049/jimmunol.0903382
  29. 29. Koenigsknecht-Talboo J, Landreth GE. Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. The Journal of Neuroscience. 2005;25:8240-8249. DOI: 10.4049/jimmunol.0903382
  30. 30. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, et al. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. The American Journal of Pathology. 2007;170:680-692. DOI: 10.2353/ajpath.2007.060378
  31. 31. Kiyota T, Okuyama S, Swan RJ, Jacobsen MT, Gendelman HE, Ikezu T. CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer’s disease-like pathogenesis in APP+PS1 bigenic mice. FASEB Journal. 2010;24:3093-3102. DOI: 10.1096/fj.10-155317
  32. 32. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: Time for reassessment. F1000Prime Reports. 2014;6:13. DOI: 10.12703/P6-13
  33. 33. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: An immunologic functional perspective. Annual Review of Immunology. 2009;27:451-483. DOI: 10.1146/annurev.immunol.021908.132532
  34. 34. Pey P, Pearce RKB, Kalaitzakis ME, Griffin WST, Gentleman SM. Phenotypic profile of alternative activation marker CD163 is different in Alzheimer’s and Parkinson’s disease. Acta Neuropathologica Communications. 2014;2:21. DOI: 10.1186/2051-5960-2-21
  35. 35. Ransohoff RM. A polarizing question: Do M1 and M2 microglia exist? Nature Neuroscience. 2016;19:987-991. DOI: 10.1038/nn.4338
  36. 36. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neuroscience Letters. 1987;79:195-200
  37. 37. Hendrickx DAE, van Eden CG, Schuurman KG, Hamann J, Huitinga I. Staining of HLA-DR, Iba1 and CD68 in human microglia reveals partially overlapping expression depending on cellular morphology and pathology. Journal of Neuroimmunology. 2017;309:12-22. DOI: 10.1016/j.jneuroim.2017.04.007
  38. 38. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Research. Molecular Brain Research. 1998;57:1-9
  39. 39. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38:1285-1291
  40. 40. McGeer PL, Itagaki S, McGeer EG. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathologica. 1988;76:550-557
  41. 41. Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer’s disease. Neurobiology of Aging. 1988;9:339-349
  42. 42. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer’s disease. Glia. 1993;7:75-83. DOI: 10.1002/glia.440070113
  43. 43. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, et al. LPS receptor (CD14): A receptor for phagocytosis of Alzheimer’s amyloid peptide. Brain. 2005;128:1778-1789. DOI: 10.1093/brain/awh531
  44. 44. Akiyama H, Nishimura T, Kondo H, Ikeda K, Hayashi Y, McGeer PL. Expression of the receptor for macrophage colony stimulating factor by brain microglia and its upregulation in brains of patients with Alzheimer’s disease and amyotrophic lateral sclerosis. Brain Research. 1994;639:171-174
  45. 45. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, et al. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer’s disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. The American Journal of Pathology. 2002;160:101-112
  46. 46. Ricciarelli R, D’Abramo C, Zingg J-M, Giliberto L, Markesbery W, Azzi A, et al. CD36 overexpression in human brain correlates with beta-amyloid deposition but not with Alzheimer’s disease. Free Radical Biology & Medicine. 2004;36:1018-1024. DOI: 10.1016/j.freeradbiomed.2004.01.007
  47. 47. Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K, Joshi JG. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathologica. 1990;81:105-110
  48. 48. Gaikwad S, Larionov S, Wang Y, Dannenberg H, Matozaki T, Monsonego A, et al. Signal regulatory protein-beta1: A microglial modulator of phagocytosis in Alzheimer’s disease. The American Journal of Pathology. 2009;175:2528-2539. DOI: 10.1016/j.freeradbiomed.2004.01.007
  49. 49. Pereson S, Wils H, Kleinberger G, McGowan E, Vandewoestyne M, Van Broeck B, et al. Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models. The Journal of Pathology. 2009;219:173-181. DOI: 10.1002/path.2580
  50. 50. Satoh J-I, Kino Y, Kawana N, Yamamoto Y, Ishida T, Saito Y, et al. TMEM106B expression is reduced in Alzheimer’s disease brains. Alzheimer's Research & Therapy. 2014;6:17. DOI: 10.1186/alzrt247
  51. 51. Matsuo A, Walker DG, Terai K, McGeer PL. Expression of CD43 in human microglia and its downregulation in Alzheimer’s disease. Journal of Neuroimmunology. 1996;71:81-86
  52. 52. Griffin WS, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer’s disease: Significance in plaque evolution. Journal of Neuropathology and Experimental Neurology. 1995;54:276-281
  53. 53. Sheng JG, Mrak RE, Griffin WS. Glial-neuronal interactions in Alzheimer disease: Progressive association of IL-1alpha+ microglia and S100beta+ astrocytes with neurofibrillary tangle stages. Journal of Neuropathology and Experimental Neurology. 1997;56:285-290
  54. 54. Walker DG, Lue L-F, Beach TG. Increased expression of the urokinase plasminogen-activator receptor in amyloid beta peptide-treated human brain microglia and in AD brains. Brain Research. 2002;926:69-79
  55. 55. Walker DG, Whetzel AM, Serrano G, Sue LI, Beach TG, Lue L-F. Association of CD33 polymorphism rs3865444 with Alzheimer’s disease pathology and CD33 expression in human cerebral cortex. Neurobiology of Aging. 2015;36:571-582. DOI: 10.1016/j.neurobiolaging.2014.09.023
  56. 56. Lue L-F, Schmitz CT, Serrano G, Sue LI, Beach TG, Walker DG. TREM2 protein expression changes correlate with Alzheimer’s disease neurodegenerative pathologies in post-mortem temporal cortices. Brain Pathology. 2015;25:469-480. DOI: 10.1111/bpa.12190
  57. 57. Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. Journal of Neuroinflammation. 2006;3:27. DOI: 10.1186/1742-2094-3-27
  58. 58. Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue L-F. Decreased expression of CD200 and CD200 receptor in Alzheimer’s disease: A potential mechanism leading to chronic inflammation. Experimental Neurology [Internet]. 2009;215(1):5-19. DOI: 10.1016/j.expneurol.2008.09.003
  59. 59. Korvatska O, Leverenz JB, Jayadev S, McMillan P, Kurtz I, Guo X, et al. R47H variant of TREM2 associated with Alzheimer disease in a large late-onset family: Clinical, genetic, and neuropathological study. JAMA Neurology. 2015;72:920-927. DOI: 10.1001/jamaneurol.2015.0979
  60. 60. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. The New England Journal of Medicine. 2013;368:107-116. DOI: 10.1056/NEJMoa1211103
  61. 61. Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. American Journal of Human Genetics. 2002;71:656-662. DOI: 10.1086/342259
  62. 62. Perez SE, Nadeem M, He B, Miguel JC, Malek-Ahmadi MH, Chen K, et al. Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer’s disease. Neurobiology of Aging. 2017;54:133-143. DOI: 10.1016/j.neurobiolaging.2017.02.012
  63. 63. Satoh J-I, Kawana N, Yamamoto Y, Ishida T, Saito Y, Arima K. A survey of TREM2 antibodies reveals neuronal but not microglial staining in formalin-fixed paraffin-embedded postmortem Alzheimer’s brain tissues. Alzheimer's Research & Therapy. 2013;5:30. DOI: 10.1186/alzrt184
  64. 64. Fahrenhold M, Rakic S, Classey J, Brayne C, Ince PG, Nicoll JAR, et al. TREM2 expression in the human brain: A marker of monocyte recruitment? Brain Pathology. 2017. DOI: 10.1111/bpa.12564
  65. 65. Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I, et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia. 2008;56:1438-1447. DOI: 10.1002/glia.20710
  66. 66. Gomez-Nicola D, Boche D. Post-mortem analysis of neuroinflammatory changes in human Alzheimer’s disease. Alzheimer's Research & Therapy. 2015;7:42. DOI: 10.1186/s13195-015-0126-1
  67. 67. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO, et al. Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: Implications for Alzheimer therapeutics. Brain Pathology. 2017;24:956-966. DOI: 10.1111/j.1365-2990.2006.00756.x
  68. 68. Haynes SE, Hollopeter G, Yang G, Kurpius D, Dailey ME, Gan W-B, et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nature Neuroscience. 2006;9:1512-1519. DOI: 10.1038/nn1805
  69. 69. Moore CS, Ase AR, Kinsara A, Rao VTS, Michell-Robinson M, Leong SY, et al. P2Y12 expression and function in alternatively activated human microglia. Neurology Neuroimmunology and Neuroinflammation. 2015;2(2):e80. DOI: 10.1212/NXI.0000000000000080
  70. 70. Ogris E, Sontag E, Wadzinski B, Narla G. Specificity of research antibodies: “Trust is good, validation is better”. Human Pathology. 2017;13:pii: S0046-8177(17)30469-0. DOI: 10.1016/j.humpath.2017.12.003

Written By

Douglas Walker and Lih-Fen Lue

Submitted: 02 November 2017 Reviewed: 15 February 2018 Published: 18 July 2018